Outcome of Living Donor Liver Transplantation for Egyptian Patients With Hepatitis C (Genotype 4)-Related Cirrhosis

Yosry, Ayman; Esmat, Gamal; El‐Serafy, Magdy; Omar, Ashraf; Doss, W.; Said, Mohamed; Abdel-bary, A. S.; Hosny, Adel; Marawan, Ibrahim; El-Malt, Osama; Kamel, Rabab; Hatata, Yaser; Ghali, A.; Sabri, H.; Kamel, S.; El-Gbaly, H.; Tanaka, Kōichi

doi:10.1016/j.transproceed.2008.03.085

Cited by 13 publications

(14 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The percentage of HCV-4 patients among recipients of OLT varies depending on the geographic location from around 29% in Saudi Arabia [120] to more than 90% in Egypt, [121] while it represents a relatively uncommon indication in the western world [122,123].…”

Section: Liver Transplantationmentioning

confidence: 99%

Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel

Khattab

Ferenci

Hadziyannis

et al. 2011

Journal of Hepatology

116

View full text Add to dashboard Cite

HCV has been classified into no fewer than six major genotypes and a series of subtypes. Each HCV genotype is unique with respect to its nucleotide sequence, geographic distribution, and response to therapy. Genotypes 1, 2, and 3 are common throughout North America and Europe. HCV genotype 4 (HCV-4) is common in the Middle East and in Africa, where it is responsible for more than 80% of HCV infections. It has recently spread to several European countries. HCV-4 is considered a major cause of chronic hepatitis, cirrhosis, hepatocellular carcinoma, and liver transplantation in these regions. Although HCV-4 is the cause of approximately 20% of the 170 million cases of chronic hepatitis C in the world, it has not been the subject of widespread research. Therefore, this document, drafted by a panel of international experts, aimed to review current knowledge on the epidemiology, natural history, clinical, histological features, and treatment of HCV-4 infections.

show abstract

Section: Liver Transplantationmentioning

confidence: 99%

Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel

Khattab

Ferenci

Hadziyannis

et al. 2011

Journal of Hepatology

116

View full text Add to dashboard Cite

show abstract

“…[36] Zimmermann, Otto & Schuchmann (2009) stated that the main HCV-cirrhosis is one of the leading indications for liver transplantation among Egyptian patients. [37] In addition, Yosry et al (2008) showed that hepatitis C related end stage liver disease (ESLD) is the leading indication for liver transplantation and appear at 89.8% of cases in Egypt. [38] As regards to chronic diseases post liver transplant, the results of the present study showed that, more than half of the studied subjects had chronic diseases such as diabetes mellitus and hypertension.…”

Section: Discussionmentioning

confidence: 99%

“…[37] In addition, Yosry et al (2008) showed that hepatitis C related end stage liver disease (ESLD) is the leading indication for liver transplantation and appear at 89.8% of cases in Egypt. [38] As regards to chronic diseases post liver transplant, the results of the present study showed that, more than half of the studied subjects had chronic diseases such as diabetes mellitus and hypertension. This finding was in agreement with Algarem, Sholkamy, Alshazly and Daoud (2014) stated that incidence of 25% were new-onset diabetes and 20% were hypertension after transplantation.…”

Section: Discussionmentioning

confidence: 99%

The effects of educational intervention on self-care behavior and expected clinical outcome in patient undergoing liver transplantation

Mohamed

Mostafa²

2018

JNEP

View full text Add to dashboard Cite

Background: Organ transplantation has the potential to rapidly restore the health and wellbeing of individuals experiencing end stage liver disease (ESLD). The aim of the research was to evaluate effects of educational intervention on self-care behaviors and expected clinical outcome in patient undergoing liver transplantation. Methods: A convenience sample of 60 liver patients was assigned for transplantation. The study was conducted in the transplanted Unit in Ain Shams University Hospitals. A quasi-experimental design with pre-post and follow up assessment has been used for this study. Tools were utilized to collect data such a) Self-care practice assessment tool, b) Patient physiological assessment sheet, and c) Demographic and medical health history tool. Results: Improvement in knowledge and self-care behaviors at the post and follow-up tests (p < .0001) after implementation of program compared by pretest evaluation. There are significant improvements in blood pressure (BP) and laboratory results through study stage (p < .001). The pain level improved after intervention and follow up (p < .0001). There are statistically significant between age, job and self-care behaviors at follow up phase. Conclusions: Liver transplantation patients showed a positive improvement in their knowledge, self-care and physiological outcomes after implementing of program. Replication of the study on larger probability sample from different geographical areas to achieve more generalizable results.

show abstract

“…Reports from Saudi Arabia reveal an overall 3-year graft and patient survival rates of 90 and 80%, respectively [24,[46][47][48][49][50]. Similarly, in Egypt, where many active living-related liver transplant programs exist and HCV-G4 represents more than 90% of cases, graft and patient survival rates are ∼86% [23].…”

Section: Introductionmentioning

confidence: 99%

“…Clinical HCV recurrence was observed in 10/38 patients (26.3%). None of the recipients developed allograft cirrhosis during the follow-up period [23]. In a recent study, Allam et al compared the outcomes of Saudi and Egyptian patients who received liver transplantation either in China or locally in Saudi Arabia (∼30% infected with HCV-G4), respective 1-and 3-year cumulative survival rates were 81 and 59% in patients transplanted in China compared with 90 and 84% for patients transplanted locally.…”

Section: Introductionmentioning

confidence: 99%

Management of Hepaitits C Virus Genotype 4 in the Liver Transplant Setting

Al–Hamoudi¹

2017

Advances in Treatment of Hepatitis C and B

View full text Add to dashboard Cite

End-stage liver disease secondary to hepatitis C virus (HCV) infection is the major indication for orthotopic liver transplantation (OLT) worldwide. It also has a negative impact on patient and graft survival leading to an inferior transplant outcome when compared to other liver transplant indications. The percentage of HCV patients infected with genotype 4 (G4) among recipients of OLT varies depending on geographic location. In the Middle East G4 infection is the most common genotype among transplant recipients. Direct antiviral agents (DAAs) have revolutionized the management of HCV infection in the pre-and post-transplant setting. Recent clinical trials have shown high sustained virologic response rates, shorter durations of treatment, and decreased adverse events when compared with the previous treatment of pegylated interferon (PEG-IFN)-based therapy. However, most of these studies were performed in HCV-G1infected patients. Due to the low prevalence of HCV-G4 in Europe and the USA, this genotype has not been adequately studied in prospective trials evaluating treatment outcomes. The aim of this chapter is to summarize the natural history and treatment outcome of HCV-G4 in the liver transplant setting, with particular attention to new HCV therapies.

show abstract

Outcome of Living Donor Liver Transplantation for Egyptian Patients With Hepatitis C (Genotype 4)-Related Cirrhosis

Cited by 13 publications

References 11 publications

Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel

Management of hepatitis C virus genotype 4: Recommendations of An International Expert Panel

The effects of educational intervention on self-care behavior and expected clinical outcome in patient undergoing liver transplantation

Management of Hepaitits C Virus Genotype 4 in the Liver Transplant Setting

Contact Info

Product

Resources

About